Patient-reported influences on COVID-19 vaccine acceptance and hesitancy in people with hidradenitis suppurativa

Jazzmin C Williams; Raed Alhusayen; Sandra Guilbault; John R Ingram; Michelle A Lowes; Christine A Yannuzzi; Haley B Naik

doi:10.1093/bjd/ljad166

Patient-reported influences on COVID-19 vaccine acceptance and hesitancy in people with hidradenitis suppurativa

Br J Dermatol. 2023 Aug 24;189(3):351-353. doi: 10.1093/bjd/ljad166.

Authors

Jazzmin C Williams¹, Raed Alhusayen², Sandra Guilbault³, John R Ingram⁴, Michelle A Lowes⁵, Christine A Yannuzzi⁶, Haley B Naik⁷

Affiliations

¹ School of Medicine, University of California, San Francisco, CA, USA.
² Dermatology Division, Department of Medicine, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
³ Hope for HS, Troy, MI, USA.
⁴ Division of Infection and Immunity, Department of Dermatology and Academic Wound Healing, Cardiff University, Cardiff, UK.
⁵ The Rockefeller University, New York, NY, USA.
⁶ HS Warriors, Binghamton, NY, USA.
⁷ Department of Dermatology, University of California, San Francisco, CA, USA.

Abstract

COVID-19 continues to pose a risk to patients with hidradenitis suppurativa (HS) due to the high prevalence of comorbidities associated with severe COVID-19 disease. We aimed to characterize perspectives on COVID-19 vaccination among patients with HS. International respondents from 20 online HS support groups were recruited to complete a voluntary, anonymous, online cross-sectional survey from 25 October to 21 November 2021 to obtain perspectives from people with HS who may and may not access healthcare. We report higher rates of COVID-19 vaccine hesitancy among patients with HS who expressed dissatisfaction with their dermatological care.

MeSH terms

COVID-19 Vaccines
COVID-19* / prevention & control
Hidradenitis Suppurativa*
Humans
Patient Reported Outcome Measures

Substances

COVID-19 Vaccines

Abstract

MeSH terms

Substances

Grants and funding